Artificial heart is successfully implanted

A bioprosthetic artificial heart has been implanted in a critically ill patient for only the third time ever in a commercial setting.

The Aeson® device – heralded as the world’s most advanced total artificial heart – offers a therapeutic alternative for people suffering from end-stage biventricular heart failure.

The implant was performed at the Department of Cardiovascular Surgery, in University Medical Centre Schleswig-Holstein (UKSH), Kiel, Germany.

Designed and developed by Carmat, this implantable bioprosthesis is continuously connected to a portable external power supply system. It was developed in response to the well-documented shortfall in heart transplants for tens of thousands of people suffering from irreversible end-stage heart failure.

It is also classed as the first physiologic heart replacement therapy, given the use of highly biocompatible materials, its unique self-regulation system and its pulsatile nature. It is hoped that the Aeson® heart could save thousands of lives without risk of rejection and with a good quality of life.

The device is the result of a collaboration between Professor Carpentier, the renowned inventor of Carpentier-Edwards® heart valves – the most used in the world – and aerospace giant Airbus Group.

It is currently commercially available in the bridge-to-transplant indication in Europe and other countries that recognise the CE mark. Aeson® is also currently being evaluated in an Early Feasibility Study in the United-States.

UKSH in Kiel, where the surgery was carried out, is one of Germany’s leading heart centres with a long history of thoracic transplantation. Prof. Assad Haneya, who performed the implant with his team, said: “We are pleased to have successfully implanted the CARMAT TAH in our centre.

“The patient who received the device suffered from severe end-stage biventricular heart failure and he was eligible for an urgent heart transplant. During the last weeks, we noticed a further deterioration with signs of a beginning multi-organ failure and the use of Aeson® was a natural choice.”

Dr. Bernd Panholzer, Director of Cardiovascular Intensive Care Unit, added: “A few days after the procedure, the device is providing all the necessary support and the patient is recovering well. Since the device has some key characteristics similar to a real heart, such as pulsatility, hemo-compatibility and self-regulation, we expect to meet the needs of many other patients placed on the waiting lists with this new type of therapy.”

Find out more at carmatsa.com.

Previous articleTaster webinar announced ahead of first-ever approved qualification in the Management of Adaptation to Climate Change
Next articleLarge-scale drug analysis reveals potential new COVID-19 antivirals